Association with pericardial disease
| HR for pericardial disease | Χ2 | P value | |
| Treatment with ICI | 7.05 (3.73 to 13.35) | 36.02 | <0.001 |
| Multivariate model | |||
| Treatment with ICI | 4.37 (2.09 to 9.14) | 15.41 | <0.001 |
| Lung cancer | 5.46 (2.96 to 10.10) | 29.35 | <0.001 |
| Prior radiation | 0.75 (0.32 to 1.79) | 0.42 | 0.52 |
| Prior pericardial disease | 2.56 (0.62 to 10.72) | 1.67 | 0.20 |
| History of cardiovascular events | 0.15 (0.02 to 1.08) | 3.56 | 0.06 |
| Platinum-based therapy | 1.17 (0.64 to 2.14) | 0.27 | 0.60 |
| Pre-ICI corticosteroid use | 1.99 (0.97 to 4.09) | 3.50 | 0.06 |
Risks of pericardial disease in the 2842 patients treated with ICI were compared with reference group including 2699 age-type and cancer-type matched patients with metastatic disease who did not receive ICI treatment (design 1).
ICI, immune checkpoint inhibitor.